JP2024540199A5 - - Google Patents

Info

Publication number
JP2024540199A5
JP2024540199A5 JP2024525780A JP2024525780A JP2024540199A5 JP 2024540199 A5 JP2024540199 A5 JP 2024540199A5 JP 2024525780 A JP2024525780 A JP 2024525780A JP 2024525780 A JP2024525780 A JP 2024525780A JP 2024540199 A5 JP2024540199 A5 JP 2024540199A5
Authority
JP
Japan
Application number
JP2024525780A
Other languages
Japanese (ja)
Other versions
JPWO2023077120A5 (https=
JP2024540199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078975 external-priority patent/WO2023077120A1/en
Publication of JP2024540199A publication Critical patent/JP2024540199A/ja
Publication of JPWO2023077120A5 publication Critical patent/JPWO2023077120A5/ja
Publication of JP2024540199A5 publication Critical patent/JP2024540199A5/ja
Pending legal-status Critical Current

Links

JP2024525780A 2021-11-01 2022-10-31 ジストロフィノパチーを処置するための筋標的化複合体 Pending JP2024540199A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274306P 2021-11-01 2021-11-01
US63/274,306 2021-11-01
PCT/US2022/078975 WO2023077120A1 (en) 2021-11-01 2022-10-31 Muscle targeting complexes for treating dystrophinopathies

Publications (3)

Publication Number Publication Date
JP2024540199A JP2024540199A (ja) 2024-10-31
JPWO2023077120A5 JPWO2023077120A5 (https=) 2026-01-19
JP2024540199A5 true JP2024540199A5 (https=) 2026-01-19

Family

ID=86158573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525780A Pending JP2024540199A (ja) 2021-11-01 2022-10-31 ジストロフィノパチーを処置するための筋標的化複合体

Country Status (9)

Country Link
EP (1) EP4426356A1 (https=)
JP (1) JP2024540199A (https=)
KR (1) KR20240095330A (https=)
CN (1) CN118201640A (https=)
AU (1) AU2022377070A1 (https=)
CA (1) CA3233308A1 (https=)
IL (1) IL312142A (https=)
MX (1) MX2024005332A (https=)
WO (1) WO2023077120A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007896A1 (en) * 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Multifunctional antibody conjugates
TW201341401A (zh) * 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
WO2016205641A2 (en) * 2015-06-17 2016-12-22 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods
TWI737736B (zh) * 2016-05-24 2021-09-01 美商薩羅塔治療公司 製備磷醯二胺嗎啉代寡聚物之方法
JP7073487B2 (ja) * 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
KR20220125801A (ko) * 2020-01-10 2022-09-14 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도

Similar Documents

Publication Publication Date Title
JP2024540199A5 (https=)
CL2025003475A1 (es) Moldeador de flujo de agua
CL2025003551A1 (es) Autoinyector y métodos de uso relacionados.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307045120S (https=)
BY13168U (https=)
BY13143U (https=)
CN307044455S (https=)
BY13142U (https=)
BY13144U (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13141U (https=)
BY13175U (https=)
BY13149U (https=)